RSLS OBALON THERAPEUTICS INC

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023

IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2023, including a corporate update on Wednesday, November 8, 2023, after market.

Management will host a conference call on November 8 at 5:00 pm ET. A live webcast will be available on the “Events and Presentations” section of ReShape’s website at: .

To access the call by phone, please register with the following , and dial-in details will be provided. Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays. An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at: .

About ReShape Lifesciences®

ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit .

CONTACTS:

Company Contact:                                       

Thomas Stankovich

Chief Financial Officer

949-276-6042

                                       

Investor Relations Contact:

Rx Communications Group

Michael Miller

(917)-633-6086

 



EN
06/11/2023

Underlying

RSLSOBALON THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OBALON THERAPEUTICS INC

 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® Announces EU MDR Certification for Entire Europe...

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively. The EU MDR, which replaced the Medica...

June 3, 2025 1 EN
 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Finan...

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Progress Towards Completion IRVINE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2025 and provided a corporate strategic update. First Quarter 2025 and Subsequent Highlights May 2025: Effected a 1-for-...

May 21, 2025 1 EN
 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split Effective as of Commencement of Trading on May 9, 2025 IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company’s common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025. At that time, each 25 shares of issued and outstanding common stock and equivalents will be conv...

May 7, 2025 1 EN
 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Di...

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will pre...

May 2, 2025 1 EN
 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent...

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device IRVINE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/241,151, entitled, “Intragastric Device.” When iss...

April 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch